Somatic mutations within tumor cells give rise to tumor-specific MHC I restricted epitopes, that can be recognized by the immune system to differentiate cancer from normal cells. Thus, generally occurring shared tumor antigens (e.g. KRAS) are candidates for cancer vaccines. A tumor antigen vaccine made of tumor antigens (peptides) stimulates the host's immune system to neutralize cancer cells. Our Clinical Peptides and Pools meet the need for high quality yet fast and affordable peptides for development of vaccines*.
Why Work with JPT?
- Two decades worth of experience in peptide drug development and peptide chemistry
- Our algorithms (based on 2.5 million synthesized peptides) rank peptides for manufacturability, stability, solubility, hydrophobicity and more
- Regulated according to ISO 9001:2015 standards
JPT’s Clinical Peptides & Pools for Clinical Grade product lines are produced in production environments regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy such as peptide vaccines. Depending on the specifics of your immunotherapy protocols, the resulting products are applicable in clinical applications.
> Further information and quote request: Clinical Peptides